Cagrilintide week 2 update: separating hype from trial data

What did @americamonserrath05 actually say?

She said cagrilintide "worked instantly the next day the first time" and then the effect seemed to disappear by week two. She's now out of the 250s in terms of her weight, which she calls "so amazing," but she's confused about why she can no longer feel the medication working. Her honest framing deserves credit. She's not overselling anything. She's asking a real question that thousands of people on GLP-1 and amylin-analog-adjacent compounds quietly wonder about.

The core claim here is twofold: that she felt a strong appetite-suppressing effect after dose one, and that dose two produced only a brief effect before fading. She frames this as something going wrong rather than something going as expected. That distinction matters quite a bit scientifically.

Does the science back this up?

Yes, actually. The "felt it then stopped feeling it" pattern is well-documented with this drug class, and it's not a malfunction. Cagrilintide is a long-acting amylin analog currently in late-stage trials, most prominently in the REDEFINE program testing the cagrilintide/semaglutide combination (CagriSema). The pharmacology explains exactly what she experienced.

Amylin analogs work partly through central nervous system pathways, including area postrema signaling, that regulate satiety and gastric emptying. The acute subjective "feeling" of the drug, often described as a sudden reduction in hunger or appetite, tends to be most noticeable when the receptor occupancy shifts sharply. After a few doses, the drug reaches a steadier plasma concentration, and that abrupt perceptual change flattens out. Knudsen et al. (2023, New England Journal of Medicine Evidence) reporting on CagriSema showed consistent weight loss across weeks even as subjective side effects plateaued. The drug working and the drug feeling like it's working are two different things.

What did they get wrong (or right)?

She got the observation right but drew a slightly wrong conclusion. Saying "what am I doing wrong?" implies user error. There's no evidence from her description that she did anything wrong. The reduced subjective sensation after dose two is pharmacologically expected, not a sign of failure or tolerance in the classical sense.

Where she could mislead her 16,000 viewers is in implying that "feeling" the medication is the metric for whether it's working. It isn't. She's already out of the 250s, which is objective progress. That outcome data matters far more than whether she feels a signal. The conflation of subjective drug sensation with drug efficacy is a real problem in GLP-1 and peptide communities on TikTok, and this video, though well-intentioned, nudges that misconception forward. To be fair, she doesn't claim the drug stopped working entirely. She's expressing confusion, not misinformation. That's an important distinction.

What should you actually know?

Cagrilintide is not FDA-approved as a standalone drug for weight management. It is an investigational compound. Any cagrilintide being used by patients right now is coming through compounding pharmacies or gray-market peptide suppliers, and the regulatory status of those sources is not equivalent to a clinical trial formulation. FormBlends does not equate compounded peptides with brand-name approved drugs, and neither should anyone making medical decisions based on a TikTok update.

The clinical data we do have is promising. A phase 2 trial by Enebo et al. (2021, The Lancet) found cagrilintide produced dose-dependent weight loss up to 10.8% over 26 weeks in people with obesity. The REDEFINE 1 trial (Lincoff et al., 2024, New England Journal of Medicine) found CagriSema, the combination product, produced roughly 22.7% weight loss at 68 weeks. But these were tightly controlled studies with verified formulations. The gap between clinical trial cagrilintide and what circulates in peptide communities is real and should not be ignored.

If the medication is working, the scale will tell you. The feeling is noise. Weight, metabolic markers, and how much you're eating are signal.

Bottom line

This is a reasonable, honest update from someone early in a drug protocol. The science mostly supports her experience. The framing that something is "wrong" because she stopped feeling the drug is the one piece worth correcting. Feeling a GLP-1 or amylin compound acutely is not a reliable efficacy indicator, and building an expectation around that feeling sets people up for unnecessary anxiety when it fades, which it is supposed to do.